Fungal Biofilms and Drug Resistance by Jabra-Rizk, Mary Ann et al.
Candida species, including the novel opportunistic
pathogen  Candida dubliniensis, are now emerging as
major agents of nosocomial infections. Many such manifes-
tations of infections associated with the formation of
Candida biofilms include those occurring on devices such
as indwelling intravascular catheters. Fungal biofilm-asso-
ciated infections are frequently refractory to conventional
therapy because of resistance to antimicrobial agents. This
resistance could be in part due to the surface-induced
upregulation of drug efflux pumps. Biofilm-associated
Candida show uniform resistance to a wide spectrum of the
currently available conventional antifungal agents, which
implies that antimicrobial drugs that specifically target
biofilm-associated infections are needed. The novel class-
es of antifungal agents, the lipid formulation of ampho-
tericins, and the echinocandins have demonstrated unique
antifungal activity against the resistant Candida biofilms,
providing a breakthrough in the treatment of life-threatening
invasive systemic mycoses. The use of drugs effective in
combating biofilm-associated infections could lead to major
developments in the treatment of fungal implant infections. 
T
he genus Candida is composed of an extremely hetero-
geneous group of organisms that grow as yeasts. Most
members of the genus also produce a filamentous type of
growth (pseudohyphae) (1). In addition to pseudohyphae,
Candida albicans and C. dubliniensis form true hyphae
(germ tubes) and thick-walled cells referred to as chlamy-
dospores, both of which are used by mycology diagnostic
laboratories in identifying these species (1). Candida
species are now emerging as major agents of hospital-
acquired infections; they are ranked as the third or fourth
most commonly isolated bloodstream pathogens, surpass-
ing gram-negative bacilli in frequency (2–9). Although C.
albicans is the predominant etiologic agent of candidiasis,
other Candida species that tend to be less susceptible to the
commonly used antifungal drugs such as C. krusei,  C.
glabrata, C. lusitaniae, and the newest Candida species,
C. dubliniensis, have emerged as substantial opportunistic
pathogens (10). Candida dubliniensis shares with C. albi-
cans many virulence factors, such as germ tube formation,
exoenzyme production, and phenotypic switching (10).
This species, however, unlike C. albicans, has been shown
to readily develop stable resistance to fluconazole in vitro
and in infected patients, strongly suggesting that C. dublin-
iensis possesses a readily inducible fluconazole resistance
mechanism (11–13).
Indwelling intravascular catheters represent a risk fac-
tor that is associated with nosocomial Candida infections.
The devices become colonized by the microorganisms that
form a biofilm of cells, the detachment of which can result
in septicemia (2–5,8,9,14,15). Most manifestations of can-
didiasis are in fact associated with the formation of
Candida biofilms on surfaces, and this phenotype is asso-
ciated with infection at both the mucosal and systemic sites
(8). Superficial Candida infections of prostheses and
implanted devices are troublesome and the most frequent-
ly encountered. One of the most common is oral denture
stomatitis, a Candida infection of the oral mucosa promot-
ed by a close-fitting upper denture present in 65% of eden-
tulous persons (5,8). 
Microbial Biofilms
Biofilms are universal, complex, interdependent com-
munities of surface-associated microorganisms. The
organisms are enclosed in an exopolysaccharide matrix
occurring on any surface, particularly aquatic and industri-
al water systems as well as medical devices. As such,
biofilms are highly relevant for public health (4,7,15–18).
Most microorganisms grow in structured biofilms rather
than individually in suspensions and while in this environ-
ment may display altered phenotypes (2). Biofilms can be
composed of a population that developed from a single
species or a community derived from multiple microbial
species (14,17). Speculations about the ecologic advan-
tages of forming a biofilm include protection from the
environment, nutrient availability, metabolic cooperation,
and acquisition of new genetic traits (3,17). Biofilms are
notoriously difficult to eliminate and are a source of many
recalcitrant infections (15,16). A variety of microbial
infections are caused by biofilms ranging from the com-
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child middle-ear infections, and dental plaque, to more
threatening infections, such as endocarditis and infections
of heart valves (16,19). Immunocompromised patients
such as those with cancer or HIV infection are often the
most susceptible.
Although bacterial biofilms and their role in disease
have been investigated in detail over a number of years,
much less is known about fungal biofilms (2,3,8,9).
Regarding oral or pharyngeal infections, to colonize and
infect the oral environment, yeast cells must first adhere to
host cells and tissues or prosthetic materials within the oral
cavity or must coaggregate with other oral microorganisms
(8,20,21). C. albicans biofilm formation has been shown in
our laboratory and others to proceed in three distinct devel-
opmental phases: early (0–11 h), intermediate (12–30 h),
and mature (38–72 h) (5) (Figure 1). The detailed structure
of a mature C. albicans biofilm produced in vitro after 48-
hour incubation has been shown to consist of a dense net-
work of yeasts, hyphae, and pseudohypha (Figure 2). This
mixture of yeasts, hyphae, and matrix material is not seen
when the organism is grown in liquid culture or on an agar
surface, which suggests that morphogenesis is triggered
when an organism contacts a surface and that the basal cell
layer may have an important role in anchoring the biofilm
to the surface (2,3,5,8). In addition, bacteria are often
found with Candida species in biofilms in vivo, indicating
that extensive interspecies interactions probably occur
(2,3,14,18,20).
Candida biofilms share several properties with bacteri-
al biofilms. The two consequences of biofilm growth with
profound clinical implications are the markedly enhanced
resistance to antimicrobial agents and protection from host
defenses, the main reasons why biofilm-associated infec-
tions are frequently refractory to conventional therapy
(2,4,5,7–9,16,18,22,23). Recently, studies showed that C.
dubliniensis has the ability to adhere to and form biofilms
with structural heterogeneity and typical microcolony and
water channel architecture similar to what has been
described for bacterial biofilms and C. albicans biofilms
(7,8). In addition, resistance of C. dubliniensis to flucona-
zole, as well as increased resistance to clinically applied
amphotericin B (8,12,13,23,24), was demonstrated in
biofilms.
Antifungal Drug Resistance
Antifungal drug resistance is quickly becoming a major
problem in the expanding population of immunocompro-
mised persons. It has resulted in a drastic increase in the
incidence of opportunistic and systemic fungal infections.
Clinical resistance is defined as persistence or progression
of an infection despite appropriate antimicrobial therapy.
Resistance is considered primary when an organism is
resistant to the drug before exposure, whereas secondary
resistance is that which develops in response to exposure
to the drug (25). This latter mechanism of resistance
accounts for the emergence of resistance to azoles seen
over the last few years. Azole antifungal agents have
become important in the treatment of mucosal candidiasis
in HIV patients. Specifically, fluconazole is considered the
drug of choice for the most common HIV-associated
opportunistic infections in the oral cavity (26). Increased
use of the azoles, coupled with the fact that they are
fungistatic drugs, has likely resulted in the emergence of
resistance to azoles. 
Major genes that contribute to drug resistance are those
coding for multidrug efflux pumps, the upregulation of
which can result in a multidrug-resistant phenotype
(2,5,9,26,27). C. albicans and C. dubliniensis possess two
different types of efflux pumps: adenosine triphos-
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Figure 1. Illustration of biofilm development in Candida albicans
and C. dubliniensis; A, early 0–11 h; B, intermediate 12–30 h; C,
mature 38–72 h; FS, flat surface; YC, yeast cell; H, hyphae; EP,
exopolymeric matrix. 
Figure 2. Typical field found in scanning electron micrograph of
biofilm formed by Candida albicans on an intravascular disc pre-
pared from catheter material.phate–binding cassette (ABC) transporters encoded by the
CDR genes (CDR1  and CDR2) and major facilitators
encoded by the MDR genes (2,12,26–28). Genes for both
types of efflux pumps have been recently demonstrated to
be upregulated during biofilm formation and development
(2,5,9). The ABC transporters CDR1 and CDR2 in C. albi-
cans and  C. dubliniensis constitute a multigene family
with a demonstrated role in resistance (5,9,12). The MDR1
gene encodes a major facilitator, the overexpression of
which leads exclusively to fluconazole resistance (5,9,12). 
Antimicrobial Drug Resistance
Microbial biofilms not only serve as a nidus for disease
but also are often associated with high-level antimicrobial
resistance, a consistent phenomenon that may explain the
persistence of many infections in the face of appropriate
antimicrobial therapy (15,29). Astudy by Ramage et al. (9)
analyzed the expression of C. albicans MDR1, CDR1, and
CDR2 genes during both planktonic and biofilm modes of
growth. Yeast biofilms were formed in the wells of
microtiter plates by pipetting standardized cell suspension
of freshly grown and washed yeast cells into wells of
microtiter plates and incubating at 37°C (9). After biofilm
formation, the medium was aspirated and nonadherent
cells were removed by thoroughly washing the biofilm.
Antifungal susceptibility testing was performed by adding
antifungal solution to the biofilms in serially diluted con-
centrations and incubating for 48 hours at 37ºC. MICs for
biofilm cells were determined by using the XTT reduction
assay, which semiquantitatively measures the metabolic
activity of the cells within the biofilm based on a color
change on the reduction of a salt that is reduced by mito-
chondrial dehydrogenases of metabolically active yeast
cells (9).
Northern blot analysis from the study showed that
mRNA levels for these genes were upregulated when the
C. albicans cells were in a sessile mode of growth com-
pared with planktonic cells, with mRNA levels for the
MDR1 gene transiently increased in 24-hour biofilms,
which indicates that efflux pumps are upregulated in cells
within a biofilm, possibly contributing to the observed
azole resistance (9). However, mutant strains deficient in
efflux pumps and hypersusceptible to fluconazole when
grown in a planktonic mode retained a resistant phenotype
during biofilm growth. This finding demonstrates that drug
resistance in biofilms is complex and involves more than
one mechanism (8).
The mechanisms by which Candida biofilms resist the
functions of antifungal agents are therefore poorly under-
stood. Factors that have been considered to be responsible
for the increased resistance to antibiotics in bacterial
biofilms include restricted penetration of antimicrobials
caused by the exopolymeric material (EP) (14). Baillie et
al. (4) analyzed the composition of C. albicans biofilms by
isolating EP from catheter tips with adherent biofilm and,
after removing the cells in suspension, concentrating and
dialyzing the supernatant. The concentrated supernatant
was then analyzed for total carbohydrate, phosphorous,
protein, glucose, and hexosamine by chemical methods
and by high-pressure liquid chromatography. Results of
that study showed that the extent of matrix formation in
Candida biofilm did not appear to affect the susceptibility
of biofilms to five clinically important antifungal agents.
The potential for drug exclusion by the biofilm matrix
that may act as a barrier to fluconazole penetration in
biofilms of mixed species of Candida and oral bacteria
seems to depend on a number of factors; data supporting
this mechanism of resistance in bacterial biofilm are strong
(2,4,7,8,17). Growth rate has been considered as an impor-
tant modulator of drug activity in bacterial biofilms.
Biofilms are thought to grow slowly because nutrients are
limited, resulting in decreased metabolism of the microor-
ganisms (2,7,8,16,29). A slow growth rate is frequently
associated with the adoption of a different phenotype by
microorganisms such as changes in the cell envelope,
which in turn affect the susceptibility of the microorgan-
ism to antimicrobial agents. In addition, virtually all
antimicrobial drugs are more effective in killing rapidly
growing cells, and some have an absolute requirement for
growth in order to kill (16). 
Regarding fungal biofilms, however, a study by
Chandra et al. (5), related to the increase of antifungal
resistance during biofilm development, showed that the
progression of drug resistance was associated with
increase in metabolic activity of the developing biofilm
and was not a reflection of slower growth rate, which indi-
cates that drug resistance develops over time, coincident
with biofilm maturation. This was the first report correlat-
ing the emergence of antifungal drug resistance with the
development of biofilm (4). 
Since the drug resistance in C. albicans biofilms cannot
be attributed solely to matrix exclusion or slow growth
rate, contact-induced gene expression for acquiring char-
acteristic properties is probably an additional mechanism
by which drug resistance is acquired (4,15). In addition,
synthesis of new proteins occurs after C. albicans attaches
to surfaces, which suggests that drug resistance might also
arise as a consequence of specific surface-induced gene
expression (4). Quantitative analysis of planktonic EP in
comparison to C. albicans biofilm EP showed that glucose
was more abundant in biofilm EP than planktonic EP, also
suggesting that C. albicans might produce biofilm-specif-
ic EP by differentially regulating genes encoding enzymes
involved in carbohydrate synthesis (4,5). In addition, the
expression profile of C. albicans genes belonging to the
ALS family, which encode proteins implicated in adhesion
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blot analysis of total RNA from planktonic and biofilm-
grown cells demonstrated that ALS gene expression is dif-
ferentially regulated between the two growth forms, with
additional genes expressed in biofilms (4,5). These obser-
vations provide further evidence for contact-induced gene
expression and transcriptional changes that are likely to
occur during biofilm formation. 
A recently proposed hypothesis on bacterial biofilm
drug resistance asserts that most cells in the biofilm may
not necessarily be more resistant to killing than planktonic
cells. Rather, a few persisters survive and are preserved by
the presence of an antimicrobial drug that slows their
growth, paradoxically helping persisters to persevere and
resist being killed. Thus persisters are ultimately responsi-
ble for the high level of biofilm resistance to killing
(8,16,22,29). The nature of persistence and whether it even
applies to fungal biofilms, however, is not clearly under-
stood. The ability to eliminate defective cells that would
otherwise drain limited resources may be a substantial
adaptive value to a clonal population such as a biofilm
community. Cells with serious defects undergo pro-
grammed cell death (PCD). Antimicrobial drugs that do
not kill cells but cause damage trigger suicide, resulting in
death from apoptosis. Persisters could represent cells with
disabled PCD as a safety mechanism aimed at preventing
suicide when a antimicrobial drug reaches the entire popu-
lation or when nutrients are limited. Therefore, inhibition
of PCD to prevent suicide allows starved cells to develop
tolerance to antimicrobial drugs (16).
With fungal biofilms serving as a safe reservoir for the
release of infecting cells into the oral or other environ-
ment, biofilm formation by C. dubliniensis and C. albicans
likely represents a key factor in their survival, with impor-
tant clinical repercussions. Treating life-threatening inva-
sive mycoses with new antifungal agents that are active
against biofilms and effective in combating biofilm-asso-
ciated infections is important. Recently, studies showed
some antibiofilm activity with the new lipid formulations
of amphotericin B and the two echinocandins (caspofungin
and micafungin), a new class of antifungals (2,24,29).
These interesting findings could lead to important devel-
opments in the treatment of fungal implant infections. 
Class of Antifungal Drugs
The antifungal agents currently available for the treat-
ment of systemic fungal infections are classified by their
site of action in fungal cells. The polyene antifungal
agents, which include nystatin and amphotericin B, are
fungicidal and have the broadest spectrum of antifungal
activity of the available agents (30,31). The polyenes cause
the fungal cell to die by intercalating into ergosterol-con-
taining membranes, the major sterol in fungal membrane,
to form channels and destroy the proton gradient in the cell
with leakage of cytoplasmic content (30,31). Intravenous
amphotericin B has been the drug of choice for invasive
fungal infections (30). The most serious side effect of
amphotericin B therapy is nephrotoxicity. To reduce the
nephrotoxicity of conventional amphotericin B, lipid for-
mulations are being used that have comparable antifungal
activity but differ in the pharmacologic and toxicologic
properties (24) 
The azoles comprise the second class of antifungal
agents and include the imidazoles (clotrimazole, micona-
zole, and ketoconazole) and the triazoles (fluconazole and
itraconazole). The azoles inhibit ergosterol biosynthesis
through their interactions with the enzyme lanosterol
demethylase, which is responsible for the conversion of
lanosterol to ergosterol in the fungal cell membrane, lead-
ing to the depletion of ergosterol in the membrane (30,31).
Fluconazole is well tolerated with very low incidence of
side effects and is the most effective agent for the treat-
ment of oropharyngeal and vaginal candidiasis, as well as
prophylaxis for fungal infections in neutropenic patients
undergoing bone marrow transplantation and for oropha-
ryngeal candidiasis in HIV-infected persons (30). 
5-Flucytosine (5-FC) is a nucleoside analog and consti-
tutes the third class of antifungal agents. After its uptake
into the fungal cell, 5-FC ultimately leads to the disruption
of DNA and protein synthesis of the fungal cell (30,31).
Flucytosine is primarily used in combination with ampho-
tericin B for the treatment of candida endophthalmitis and
cryptococcal meningitis (30,31). 
New Classes of Antifungal Drugs
The echinocandins and their analogs, the pneumocan-
dins, represent the newest class of antifungal drugs
(19,29,31–40). They inhibit the synthesis of 1,3-β-D-glu-
can, a fundamental component of the fungal cell wall by
the inhibition of 1,3 β-D-glucan synthase, an enzyme com-
plex that forms glucan polymers in the cell wall and is
absent in mammalian cells. The inhibition is effective and
specific, and brief exposure leads to cell death. The potent
antifungal activity of the echinocandins against Candida
species was demonstrated by Cuenca-Estrella et al. (33)
and Quindos et al. (24), who evaluated the in vitro activity
of LY303366, a semi-synthetic echinocandin B derivative,
against 156 clinical isolates of Candida species and 36 C.
dubliniensis clinical isolates, respectively. Results showed
that LY303366 had potent activity against several Candida
species including C. albicans, C. tropicalis, as well as C.
glabrata and  C. krusei, two species usually considered
refractory to azoles. Similarly, 100% of the isolates were
susceptible to the new antifungal drugs, indicating that
echinocandins may provide new alternatives to flucona-
zole for treating C. dubliniensis infections (24). The excel-
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against fluconazole-resistant Candida species strains indi-
cates that the echinocandins are very promising as novel
antifungal agents with important implications for the treat-
ment of infections by these yeasts (24,33,34). Their unique
mode of action and their specificity to fungal cell walls
result in minimal toxicity to mammalian cells. 
Discussion
By using models of C. albicans biofilms, several stud-
ies have shown uniform resistance of the organisms in the
biofilm to a wide spectrum of conventional antifungal
agents including resistance to the new triazoles (VRC and
Ravu), which have been shown to be fungicidal with
extended activity against many azole-resistant organisms.
Therefore, biofilm-associated infections are difficult to
treat, which emphasizes the need to develop antimicrobial
drugs that show activity against biofilm-associated organ-
isms and specifically target biofilm-associated infections
(5,19). The novel classes of agents, namely the lipid for-
mulation of amphotericins and the echinocandins, have
been shown to have unique activities against the resistant
Candida biofilms (19,29). However, given their large size,
that liposomal amphotericin B formulations could pene-
trate ECM to target the fungal cell wall is somewhat sur-
prising. Their dispersion in phospholipids may in fact
facilitate passage through the charged polysaccharide
ECM, which may be the mechanism by which these com-
pounds penetrate tissues (29). The mechanism of the
echinocandins against biofilm cells is still unclear. The
echinocandins probably do not exert their antibiofilm
effects primarily on the fungal cell wall since only minimal
cellular changes have been observed on biofilm-associated
Candida cells. One explanation may lie in their potential
effect on ECM kinetics, where the inhibition of polysac-
charide production by echinocandins could lead to lysis
and dissolution of the ECM (29). Further studies to deter-
mine the exact mode of action of echinocandins on
Candida biofilms are warranted.
In conclusion, the amphotericin B lipid formulations
and the echinocandins exhibit novel activity against
Candida biofilms. The use of these drugs may represent an
important step in the treatment of invasive systemic
Candida infections by enhancing retention of affected
intravascular devices and obviating the need for valve sur-
gery in Candida endocarditis (2,19,29). More importantly,
these antifungal drugs may be useful in management of
biofilm infections by fungi and may have other clinical
applications including those of oral diseases and prosthe-
ses rejection.
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